



ASX ANNOUNCEMENT

ASX:NSB

NEUROSCIENTIFIC UPCOMING EVENTS AND PRESENTATIONS

Perth, Australia, 21 August 2018 - NeuroScientific Biopharmaceuticals Limited (ASX:NSB), a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical need, is pleased to announce its scheduled promotional activity for the remainder of the 2018 calendar year.

Event	Location	Date
AusBioTech Invest & Partnering 2018	Perth, WA	30 October
TechKnow Invest Roadshow	Sydney NSW	30 October
TechKnow Invest Roadshow	Melbourne VIC	1 November
121 Tech Invest	Singapore	4 – 5 December

To arrange a meeting with representatives from NeuroScientific at any of these events, or for more information on any of NSB's products and development activities, please contact Matt Liddelow, CEO and Managing Director:

Telephone: +61 8 6382 1805

Email: ml@neuroscientific.com

About NeuroScientific Biopharmaceuticals Limited

NeuroScientific (ASX:NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company's product portfolio includes EmtinB, a therapeutic peptide initially targeting Alzheimer's disease; 15mS.A. which is being developed as a diagnostic peptide for early-stage Alzheimer's disease; and other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB. For more information, please visit www.neuroscientific.com

Contacts

Mr Matthew Liddelow
CEO and Managing Director
ml@neuroscientific.com
+61 8 6382 1805

Thomas Spencer
CFO & Company Secretary
ir@neuroscientific.com
+61 491 108 250